Central African Republic (the)

in page functions
[French]
Central African Republic
Total population (2018) 5,200,905
Birth cohort (2018) 167,723
Surviving Infants (surviving to 1 year per year, 2018) 153,866
Infant mortality rate (deaths < 1 year per 1000 births, 2015) 92/1000
Child mortality rate (deaths < 5 years per 1000 births, 2015) 130/1000
World Bank Index, IDA (2015) 2.46
Gross Nation Income (per capita US$, 2015) 330
Co-financing group (2018) Initial self-financing
No. of districts/territories (2017) 30

Contact Gavi

For more info, contact Gavi country representative officer or email here

Gavi support for Central African Republic

Type of support

Approvals

2001-2022 (US$)
(22 Aug 2018)

Commitments

2001-2022 (US$)
(22 Aug 2018)

Disbursements

2000-2018 (US$)
(22 Aug 2018)

% Disbursed

(22 Aug 2018)
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
Total $42,859,842 $44,647,525 $41,205,144
Health system strengthening (HSS 1) $3,163,000 $3,163,000 $3,163,000 100%
Health system strengthening (HSS 2) $7,480,817 $9,000,000 $6,040,817 81%
Immunisation services support (ISS) $1,611,360 $1,879,860 $1,611,360 100%
Injection Safety Devices (NVS) $113,416 $113,416 $132,142 117%
Injection safety support (INS) $119,651 $119,651 $119,651 100%
IPV (NVS) $587,881 $587,881 $599,370 102%
Meningitis A (NVS) $133,892 $133,892 $133,256 100%
Meningitis A - campaign (NVS) $2,933,000 $2,933,000 $2,953,250 101%
Meningitis A - operational costs (OPC) $2,342,943 $2,342,943 $2,342,943 100%
Penta (NVS) $8,297,213 $8,297,213 $8,378,265 101%
Pneumo (NVS) $13,384,650 $13,384,650 $13,389,305 100%
Rotavirus (NVS) $194,000 $194,000 0%
Vaccine Introduction Grant (VIG) $647,321 $647,321 $508,321 79%
Yellow Fever (NVS) $1,850,698 $1,850,698 $1,833,464 99%

Red line on table indicates duration of support based on commitments.
Commitments: Multi-year programme budgets endorsed in principle by the Gavi Board. These become financial commitments upon approval each year for the following calendar year.
Approvals: Total Approved for funding

Download data for commitments, approvals & disbursements in XLS format

Central African Republic DTP3 / immunisation coverage

DTP3 - WHO/UNICEF estimates (2017)

Grade of confidence


N/A
DTP3 - Official country estimates (2017) 53%
M:F sex ratio at birth (2018) 1.03
Household survey: DTP3 coverage for male (2009) 33.10%
Household survey: DTP3 coverage for female (2009) 31.10%
Household survey: Last DTP3 survey (2009) 32%
% districts achieving > 80% DTP3 coverage (2017) 20%
% districts achieving < 50% DTP3 coverage (2017) 40%
MCV WHO/UNICEF estimates (2017) 49%

Breakdown of support

Non-vaccine support Vaccine support
33% 67%
$13,786,092 $27,419,052

Data refers to disbursed values, date as per above chart

Move mouse over graph for details

News and updates relating to Central African Republic

29 November 2017

Anuradha Gupta PEF

Engaging partners for success

Gavi’s Deputy CEO Anuradha Gupta gives the lowdown on how a little-known acronym - PEF (Partners' Engagement Framework) - has pioneered new ways of working with development organisations.

25 April 2017

Central African Republic, a mother and her two children.

Central African Republic: mother spreads word about meningitis A vaccine

Izimili Raude knows that her community must rely on vaccines, not miracles, to spare children from a deadly disease.

19 September 2016

Stockpiling

On the frontline: Gavi's support to fragile states

With more than half of Gavi-supported countries officially listed as fragile states, Gavi is increasingly working on several fronts to ensure vaccines still reach people living on the frontlines of humanitarian crises.

Disclaimer: the boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of Gavi, the Vaccine Alliance concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

close icon

modal window here